All Posts

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3 Sparsentan data readout in 2021 Other exciting kidney readouts in 2023 include PROK Ph2/3 data and CARA Ph3 data; and Ph3 KDNY data and Ph3 OMER data in IgAN. TVTX's asset Sparsentan has a PDUFA target action date of February 17, 2023 for the possible treatment of IgA Nephropathy. Sparsentan is a dual endothelin angiotensin receptor antagoni

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers such as prostate cancer and ovarian cancer Several smid-cap biopharmas are presenting data at ASCO-GU, including final results from BTAI We have also determined additional upcoming late stage trials in GU cancers in the next year   ASCO-GU 2023 starts February 16 and focuses on new and innovative findings and studies for the treatment of ge

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including GTHX phase 3 data in Feb , ASCO-GU meeting  mid Feb, and lots of Alzheimer's readouts  throughout the year. The table below highlights catalysts coming in the next few weeks to keep an eye on. Connect with us & fellow traders in our Discord chat  (drop me a message that you're premium to access the premium chat channels). BPIQ Weekly Cataly

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial...

Originally posted 1/25/23; last updated 4/13/23 Summary: Many exciting Alzheimer's disease catalysts are coming throughout the year See...

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial PFS data expected in Q4 2023 So far no CRC data from Trilaciclib has been reported - Ph2 data was from breast cancer patients Get Amp's view/post  of GTHX ahead of the mCRC data. If you are a BPIQ Pro member, contact support@BPIQ.com  to for help adding an Amp subscription. Trilaciclib Trilacaclib is a small molecule cylin-dependent kinase (

Summary: SAVA Ph2 Open label study topline data was reported today, 1/24/23 While the data was reported as positive, the market did not...